Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597987 · ClinicalTrials.gov registry record
BRCA1 Haploinsufficiency and Gene Expression
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 120
- Enrollment target
NCT00597987: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00597987 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00597987 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to collect a blood sample from patients that may be used for research purposes. These blood samples will be used by researchers at this institution to study the causes of breast and ovarian cancer, and to better understand how these cancers develop. We are trying to discover differences in the ways cells work in women with a high genetic risk of developing breast or ovarian cancer. Early data suggest that some genes may be turned on or off in different ways based upon whether or not a woman has a high genetic risk of developing breast or ovarian cancer. The primary objective is to test the hypothesis that BRCA1 haploinsufficiency regulates gene expression on the X chromosome. This hypothesis will be tested by comparing the gene expression profiles of BRCA1 heterozygotes (cases) to an age-matched group of unaffected women who are not BRCA1 mutation carriers (controls).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2004-09 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00597987
The ClinicalTrials.gov registry entry for NCT00597987 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00597987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00597987 about?
NCT00597987 is a clinical study titled "BRCA1 Haploinsufficiency and Gene Expression". The purpose of this study is to collect a blood sample from patients that may be used for research purposes. These blood samples will be used by researchers at this institution to study the causes of breast and ovarian cancer, and to better understand how these cancers develop. We are trying to disc...
What is the current status of trial NCT00597987?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2004-09. Estimated completion is 2012-09.
Who is sponsoring clinical trial NCT00597987?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.